Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MNV-201

Phase 2Biologic

MMinovia Therapeutics Ltd.

2

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mitochondrial DiseasesRecruiting

Low RiskRecruiting

Mitochondrial DiseasesPhase 2

Recruiting

Low RiskPhase 1

Recruiting

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Mitochondrial Diseases

NCT06017869

Q4 2029

Phase 1Recruiting

Low Risk

NCT06465160

Clinical

Trials by Indication[1]

Low Risk1 trial

A Study to Evaluate the MNV-201 in Patients With Low Risk MDS

Recruiting·MMinovia Therapeutics Ltd.·Phase 1·NCT06465160·15 enrolled

Mitochondrial Diseases1 trial

PHASE II, OPEN LABEL, SINGLE DOSE STUDY OF THE SAFETY AND EFFICACY OF MNV-201 FOR THE TREATMENT OF PEARSON SYNDROME

Recruiting·MMinovia Therapeutics Ltd.·Phase 2·NCT06017869·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MNV-201. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MNV-201 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MNV-201. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Minovia Therapeutics Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: MMinovia Therapeutics Ltd.

Related News